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Background: Patient navigation (PN) is a patient-centered health-care service delivery 
model that assists individuals, particularly the medically underserved, in overcoming 
barriers (e.g., personal, logistical, and system) to care across the cancer care continuum. 
In 2012, the American College of Surgeons Commission on Cancer (CoC) announced 
that health-care facilities seeking CoC-accreditation must have PN processes in place 
starting January 1, 2015. The CoC mandate, in light of the recent findings from centers 
within the Patient Navigation Research Program and the influx of PN interventions, war-
rants the present literature review.
Methods: PubMed and Medline were searched for studies published from January 2010 
to October 2015, particularly those recent articles within the past 2 years, addressing 
PN for breast and gynecological cancers, and written in English. Search terms included 
patient navigation, navigation, navigator, cancer screening, clinical trials, cancer patient, 
cancer survivor, breast cancer, gynecological cancer, ovarian cancer, uterine cancer, 
vaginal cancer, and vulvar cancer.
Results: Consistent with prior reviews, PN was shown to be effective in helping women 
who receive cancer screenings, receive more timely diagnostic resolution after a breast 
and cervical cancer screening abnormality, initiate treatment sooner, receive proper 
treatment, and improve quality of life after cancer diagnosis. However, several limitations 
were observed. The majority of PN interventions focused on cancer screening and diag-
nostic resolution for breast cancer. As observed in prior reviews, methodological rigor 
(e.g., randomized controlled trial design) was lacking.
Conclusion: Future research opportunities include testing PN interventions in the 
post-treatment settings and among gynecological cancer patient populations, age- 
related barriers to effective PN, and collaborative efforts between community health 
workers and patient navigators as care goes across segments of the cancer control 
continuum. As PN programs continue to develop and become a standard of care, further 
research will be required to determine the effectiveness of cancer PN across the cancer 
care continuum, and in different patient populations.
Keywords: patient navigation, breast cancer, cervical cancer, gynecological cancers, women’s health, cancer 
disparities
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iNTRODUCTiON
Profound advances in cancer screening, reductions in the 
prevalence of risk factors, and development of more effective 
treatments have positively contributed to increased longevity and 
quality of life among cancer survivors. Despite these improve-
ments, disparities by race/ethnicity and socioeconomic status 
remain in cancer prevention, incidence, treatment, and mortality 
(1, 2). One approach to reduce cancer disparities is through 
patient navigation (PN). PN is a patient-centered, health-care 
service delivery model that assists individuals, particularly the 
medically underserved, in overcoming barriers to care (e.g., 
personal, logistical, system) across the cancer care continuum. 
PN is “navigation” in the health-care system compared to out-
reach, which is in the community and can use lay health advisors, 
community health workers (CHWs), etc. Typically, CHWs are 
trusted community members who provide information, sup-
port, and encouragement to receive screening tests (3). Previous 
intervention studies using CHWs to promote cancer screening 
have reported significantly increased screening rates for breast 
and cervical cancer (3, 4). CHWs and patient navigators differ 
in that CHWs work in the community, and their role ends when 
the patient enters the health-care facility. Patient navigators are 
typically housed in clinics; however, both the CHW and patient 
navigator complement each other in that they serve as a bridge 
between the health-care system and members of underserved 
communities.
Patient navigation began in 1990 by Harold Freeman who 
developed a PN program within a public hospital in Harlem, 
NY, USA to provide assistance to low-income women in need of 
breast cancer screening and timely follow-up to reduce diagno-
ses of late-stage breast cancer (5). Due to the promising results 
from Freeman’s initial PN program and continued evidence of 
effectiveness, PN has grown nationally as a standard of care (6, 
7). PN studies have demonstrated that PN can improve rates of 
cancer screening (8, 9), ensure follow-up rates after an abnormal 
screening test (10, 11), and improve cancer care outcomes (i.e., 
time to treatment, quality of life) (12, 13).
Several recent literature reviews including Robinson-White 
et al. (14), Paskett et al. (15), and Wells et al. (16) have described 
the evolution of PN as a model to address cancer disparities. In 
2011, a literature review by Paskett et al. (15) provided an update 
to the 2008 review by Wells et  al. (16) on the efficacy of PN 
for cancer care. Paskett et al. (15) found that within the 3-year 
window since Wells’ review, the quantity of work in cancer PN 
literature was comparable to that of the previous years combined. 
In both reviews, most studies provided evidence for the effective-
ness of increasing cancer screening rates including breast and 
gynecological cancers (15, 16). However, a paucity of research 
focusing on PN among cancer survivors during and after primary 
treatment and methodological limitations (i.e., lack of rigorous 
study design) of PN interventions were noted.
Since the 2011 literature review, many additional PN programs 
have been implemented especially those within the Patient 
Navigation Research Program (PNRP), funded by the National 
Cancer Institute (17) with support from the American Cancer 
Society (ACS). Active from 2005 to 2010, the PNRP provided 
funding to 10 institutions nationwide to develop and test interven-
tions for follow-up and the initiation of treatment for four cancers 
for approved, validated screening tests: breast, cervical, prostate, 
and colorectal (18). Although any individual could benefit from 
PN, the PNRP focused efforts to identify and address barriers to 
care among populations experiencing cancer health disparities.
Breast and gynecological cancers are an optimal arena to 
use PN because of the known survival benefit of early detection 
through mammography and Pap tests with prompt follow-up of 
detected abnormalities. PN is particularly important in women’s 
cancers because of documented racial and ethnic disparities in 
cancer care across disease trajectories. In 2015, cervical cancer 
incidence rates among Hispanic women were the highest of any 
racial/ethnic group, 50% higher than those among non-Hispanic 
whites (19). In addition, the death rate for cervical cancer in black 
women was double than that in non-Hispanic white women (2.0 
vs. 4.2 per 100,000, respectively) (19). It is notable that although 
white women had the highest breast cancer incidence rate, black 
women had the highest breast cancer mortality rate (19, 20). 
Thus, PN may be a strategy to help reduce these documented 
disparities.
The purpose of this review is to: (a) provide a summary of the 
recent literature (2010–2015) on PN and breast and gynecologic 
cancers from screening through treatment along the cancer care 
continuum; and (b) highlight research challenges and opportuni-
ties of PN that impact women’s health.
MeTHODS
PubMed and Medline were searched for studies published from 
January 2010 to October 2015, particularly those recent articles 
within the past 2 years, addressing PN for breast and gynecologi-
cal cancers and written in English. Only original studies reporting 
quantitative, qualitative, or mixed methods results regarding PN 
that dealt with cancer screening, diagnosis, treatment, clinical 
trials, or survivorship were included in this review. Editorials, 
abstracts, anecdotal reports, literature reviews, and articles lack-
ing data from original research were excluded, as were articles 
that included non-breast/non-gynecological cancers and/or men 
in the analyses. Search terms included patient navigation, naviga-
tion, navigator, cancer screening, clinical trials, cancer patient, 
cancer survivor, breast cancer, gynecological cancer, ovarian 
cancer, uterine cancer, vaginal cancer, and vulvar cancer.
A total of 209 articles referencing PN in women’s cancers 
were found, of which 180 did not meet the inclusion criteria, 
resulting in 29 articles that met the criteria for inclusion in this 
review. Several notable PNRP articles were excluded because they 
included non-breast/non-gynecological cancer and men in their 
analyses (21–25). The 29 articles were then divided into categories 
along the cancer care continuum (screening, diagnostic resolu-
tion, and after primary diagnosis). The articles were reviewed 
and summarized by one study author (Jessica L. Krok-Schoen). 
Questions regarding inclusion were resolved by consensus among 
the other two authors (Jill M. Oliveri and Electra D. Paskett). Each 
article was reviewed, and the results presented are organized by 
placement along the cancer care continuum described above. 
TABLe 1 | Summary of published cancer patient navigation studies: 2010–2015.
Reference Cancer Design Participants Results
PATieNT NAviGATiON FOR CANCeR SCReeNiNGS
Burhansstipanov 
et al. (26)
Breast Natural 
experiment then 
a quasi-control 
study
313 African American, Latina, Native American, 
and poor White women who had not received a 
mammography in more than 18 months enrolled 
in a navigation intervention
Navigation improved mammography among women for all racial/
ethnic groups who received the navigation intervention compared 
to those women in the non-navigated group
Marshall et al. (27) Breast Randomized 
controlled trial
1,358 African American female Medicare 
beneficiaries who were ≥65 years of age 
randomized to receive either patient navigation 
and educational materials (n = 638) or 
educational materials only (n = 720)
Women in the intervention group had significantly higher odds 
of being up to date on mammography screening compared 
to women in the education only group (OR = 2.26, 95% 
CI = 1.59–3.22)
Percac-Lima et al. 
(28)
Breast Quasi-
experimental 
intervention
91 Serbo-Croatian speaking women overdue 
or never had a mammogram who received 
individually tailored interventions to encourage 
breast cancer screenings
At baseline, 44.0% of women had a mammogram within the 
previous year, with the proportion significantly increasing to 67.0% 
after 1 year (p < 0.001)
Percac-Lima et al. 
(29)
Breast Quasi-
experimental 
intervention
188 refugee women eligible for breast cancer 
screening at an urban community health center. 
The comparison group was English (n = 2,072) 
or Spanish-speaking (n = 2,014) women eligible 
for breast cancer screening
Patient navigation increased screening rates in both younger and 
older refugee women (64.1% before intervention, 81.2% after 
intervention) and were similar to the English (80.0%) and Spanish-
speaking women (87.6%)
Phillips et al. (30) Breast Controlled 
cluster 
randomized trial
3,895 inner city women were randomized to a 
phone-based navigation intervention (n = 1,817) 
and usual care (n = 2,078) groups
At baseline, there was no difference in mammography adherence 
between the usual care and intervention groups. After the 
9-month intervention, mammogram adherence was significantly 
higher in the intervention group (87.0%) compared with the usual 
care group (76.0%) (p < 0.001)
Wang et al. (31) Cervical Two-arm, quasi-
experimental 
pilot study
Chinese women (n = 134) who has not had 
a Pap test within the previous 12 months 
assigned to either patient navigation (education 
and navigation services) (n = 80) and control 
(education only) (n = 54) groups
In the 12 months following the program, Pap screening rates were 
significantly higher in the intervention group (70.0%) compared to 
the control group (11.1%) (p < 0.001)
PATieNT NAviGATiON FOR DiAGNOSTiC ReSOLUTiON
Basu et al. (32) Breast Pre-post 
design, quasi-
experimental 
intervention
176 women diagnosed with breast cancer 
enrolled in a nurse navigation program to 
increase timeliness to diagnostic resolution and 
consultation
Navigation was found to significantly shorten time to consultation 
for women older than 60 years but not for women 31-60 years 
of age
(Continued)
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Table 1 comprises a summary of published cancer PN studies 
(N = 29).
ReSULTS
PN for Cancer Screening
The literature on PN interventions to increase breast cancer 
screening included five studies (26–30), with two randomized 
controlled trials (RCTs) (27, 30). In a large RCT with 3,895 inner 
city women, Phillips et  al. (30) found no statistical difference 
in mammography adherence between the control (usual care) 
and PN intervention groups at baseline. After the 9-month 
intervention, mammogram adherence was significantly higher 
in the PN intervention group compared to the control group 
(87 vs. 76%, respectively, p < 0.001). Marshall et al. (27) imple-
mented a RCT to increase breast cancer screening among 1,905 
older African American Medicare beneficiaries. Women in the 
intervention group who received educational materials and PN 
services had significantly higher odds of being within guidelines 
for mammography screening at the end of the 2-year follow-up 
period compared to women in the control group who received 
only educational material [odds ratio (OR) =  2.26, 95% confi-
dence interval (CI) = 1.59–3.22].
The other three studies (26, 28, 29) examined the effective-
ness of PN interventions to increase breast cancer screening 
among diverse populations, including African American, 
Latina, Native American (26), immigrant (28, 29), and refugee 
(28, 29) women. Burhansstipanov et  al. (26) implemented an 
education-based PN intervention to facilitate mammography 
screening for African American, Latina, Native American, and 
poor white women in the Greater Denver Metropolitan area. 
Statistically significant associations were found between having 
received the PN intervention and reporting a mammogram 
screening for all racial/ethnic groups (p <  0.05). A study by 
Percac-Lima et al. (28) implemented an educational, language 
concordant PN program for Serbo-Croatian refugees and 
immigrants to overcome barriers to breast cancer screening 
and support them in scheduling a mammogram. They found 
that, at baseline, 44% of women had a mammogram within 
Reference Cancer Design Participants Results
Battaglia et al. (33) Breast, 
cervical
Quasi-
experimental 
intervention
Women with abnormal breast and cervical 
cancer screenings who were enrolled in the 
navigator intervention (n = 1,497) or usual care 
(n = 1,544) arm in the Boston Patient Navigation 
Research Program
There was a significant decrease in time to diagnostic resolution 
for navigated group compared with usual care group among 
those with a cervical screening abnormality (aHR = 1.46; 95% 
CI = 1.1–1.9); and among those with a breast cancer screening 
abnormality that resolved after 60 days (aHR = 1.40; 95% 
CI = 1.1–1.9). There was no difference before 60 days
Charlot et al. (34) Breast, 
cervical
Quasi-
experimental 
intervention
Women with a breast (n = 655) or cervical 
(n = 602) cancer screening abnormality enrolled 
in the Boston Patient Navigation Research 
Program
Language concordance was associated with timelier diagnostic 
resolution for all women of the cervical cancer screening 
abnormality group during the first 90 days (aHR = 1.46; 95% 
CI = 1.18–1.80), but not after 90 days. Race concordance 
was associated with significant decreases in time to diagnostic 
resolution for minority women with breast and cervical cancer 
abnormalities
Donelan et al. (35) Breast Group 
comparison 
study
72 women with abnormal mammography 
enrolled in a navigator program. 181 women 
with abnormal mammography were in the non-
navigated group
There was no difference in timeliness of care, preparation for the 
visit to the breast center, ease of access, quality of care, provider 
communication, unmet needs, and patient satisfaction between 
groups
Dudley et al. (36) Breast Quasi-
experimental 
intervention
460 low-income Hispanic women (260 
navigated, 200 usual care) with an abnormal 
breast cancer screening result or untreated 
biopsy in the University of Texas Patient 
Navigation Research Program
The average days from definitive diagnosis to initiation of therapy 
was significantly reduced overall with navigation (navigation vs. 
usual care, 57 vs. 74 days, p < 0.05)
Freund et al. (37) Breast Meta analyses 3,083 women with abnormal breast cancer 
screening tests and 1,455 women with 
abnormal cervical cancer screening tests who 
participated in the Patient Navigation Research 
Program
One out of seven sites focused on abnormal breast cancer 
screening and two out of four sites focused on abnormal 
cervical cancer screening reported a significant benefit of PN on 
diagnostic resolution after cancer screening abnormality from 0 
to 90 days
Three out of seven sites focused on abnormal breast cancer 
screening and 2 out of four sites focused on abnormal cervical 
cancer screening reported a significant benefit of PN during 
91–365 days
Hoffman et al. (38) Breast Prospective, 
pre-post study
2,601 women (1,047 navigated, 1,554 usual 
care) with abnormal breast cancer screening 
result/clinical abnormality enrolled in the DC 
City-wide Patient Navigation Research Program
The average number of days to diagnostic resolution was 
significantly shorter for navigated women than non-navigated 
women (25.1 vs. 42.1 days, respectively, p < 0.001), particularly 
among women who had a biopsy (p < 0.001)
Lee et al. (39) Breast Controlled 
cluster 
randomized trial 
design
1,039 (494 navigated, 545 usual care) women 
with abnormal breast cancer screening result/
clinical abnormality enrolled in the Moffitt Patient 
Navigation Research Program
Patient navigation did not increase the timeliness of diagnostic 
resolution during the initial 3 months of follow-up but started to 
reduce time to diagnostic resolution after 3 months (aHR = 2.8, 
95% CI = 1.30–6.13) and had a significant effect after 4.7 months 
(p < 0.05)
Luckett et al. (40) Cervical, 
vulvar
Descriptive 
study
4,199 women at a tertiary care referral 
colposcopy center implementing a patient 
navigator program to reduce non-show rates
No-show rates declined from 49.7 to 29.5% after implementation 
of the patient navigator program 
Markossian et al. 
(41)
Breast, 
cervical
Quasi-
experimental 
intervention
Underserved women with abnormal breast or 
cervical screening test results were assigned to 
either patient navigation intervention (n = 355) 
(the Chicago Cancer Navigation Project) or 
usual care groups (n = 413)
Compared with the usual care group, the breast navigation group 
had shorter time to diagnostic resolution (aHR = 1.65, 95% 
CI = 1.20–2.28) and the cervical navigation group had shorter 
time to diagnostic resolution for those who resolved after 30 days 
(aHR = 2.31, 95% CI = 1.75–3.06), with no difference before 
30 days
Paskett et al. (42) Cervical Meta-analysis 2,317 women with low and high-risk cervical 
abnormalities from four Patient Navigation 
Program centers who received patient 
navigation (n = 1332) or usual care (n = 985)
Low-risk women in the navigated group showed improvement 
in timely diagnostic follow-up in all racial groups, but significant 
effects were only observed in non-English speaking Hispanic 
women (OR = 5.88, 95% CI = 2.81–12.29). No effect was 
observed in high-risk women
Percac-Lima et al. 
(43)
Cervical Quasi-
experimental 
intervention
533 Latina women with an abnormal Pap 
smear requiring colposcopy received patient 
navigation. The comparison group was 253 
non-navigated Latinas with an abnormal Pap 
smear requiring colposcopy
Navigated women had significantly fewer missed colposcopy 
appointments over time, with the average falling from 19.8 to 
15.7% (p < 0.05), compared with an insignificant increase in the 
no-show rates from 18.6 to 20.6% in the comparison group
Raich et al. (44) Breast Randomized 
clinical trial
628 patients with abnormal breast screenings 
tests randomized to either intervention (n = 308) 
or usual care (n = 320) arms in the Denver 
Patient Navigation Research Program
For the abnormal breast screening group, 92% of the navigated 
patients reached diagnostic resolution of the initial abnormal test, 
as compared with 77% for the usual care patients (p < 0.001)
TABLe 1 | Continued
(Continued)
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Reference Cancer Design Participants Results
Ramirez et al. (45) Breast Prospective, 
pre-post study
425 Latina women with abnormal breast cancer 
screening results enrolled in either a patient 
navigator program (Six Cities Patient Navigation 
Study) (n = 217) or usual care (n = 208)
The time to diagnosis was shorter in the navigated group 
(mean, 32.5 vs. 44.6 days in the usual care group; HR = 1.32). 
Navigation significantly shortened the time to diagnosis among 
women who had BI-RADS-3 radiologic abnormalities (mean, 
21.3 vs. 63.0 days; HR = 2.42); but not among those who had 
BI-RADS-4 or 5 (mean, 37.6 vs. 36.9 days; HR = 0.98)
PATieNT NAviGATiON AFTeR PRiMARY DiAGNOSiS
Chen et al. (46) Breast Pre-post 
design, quasi-
experimental 
intervention
100 newly diagnosed women with breast 
cancer who were enrolled in a navigator 
program (n = 51) and non-navigated (n = 49)
Overall adherence to the quality indicators significantly improved 
from 69 to 86% (p < 0.01) with the use of patient navigators. 
Only one individual indicator, use of surveillance mammography, 
significantly improved (52–76%, p < 0.05) for the navigated 
women, not for the non-navigated women
Haideri and 
Moormeier (47)
Breast Retrospective 
case series 
analysis
157 women who received navigation services 
and 103 women who received usual care after 
being diagnosed with breast cancer
There was no difference in the stage of presentation or the overall 
survival between the intervention and usual care groups. For the 
navigated women, there was a modest decrease (9 days) in the 
time between initial presentation and definitive therapy
Hendren et al. (48) Breast Randomized 
controlled trial
319 newly diagnosed breast cancer patients 
were randomized to receive a patient navigation 
intervention for improved quality of life (n = 141) 
or usual care (n = 129) in the University of 
Rochester Patient Navigation Project
There was no significant effect of patient navigation on disease-
specific quality of life scores between navigated and usual care 
breast cancer patients undergoing primary cancer treatment
Ko et al. (49) Breast Multisite, quasi-
experimental 
intervention
1,004 (navigated = 498, usual care = 506) 
women newly diagnosed with breast cancer 
enrolled in the Patient Navigation Research 
Program to improve receipt of recommended 
care
Among women eligible for antiestrogen therapy, navigated women 
had a significant higher likelihood of receiving antiestrogen therapy 
compared with non-navigated controls (OR = 1.73, p < 0.01). 
Among the women eligible for radiation therapy after lumpectomy, 
navigated women were no more likely to receive radiation than 
women in the usual care group (OR = 1.42, p = 0.22)
Madore et al. (50) Breast Quasi-
experimental 
pilot study
20 medically underserved women recently 
diagnosed with breast cancer who were 
enrolled in the Breast CARES intervention to 
overcome treatment barriers
There was a decrease in depression and cancer-related distress 
and an increase in social support. Participation in the intervention 
helped the women overcome financial barriers (73.0%), 
transportation problems (60.0%), and communication barriers 
with medical staff (73.0%)
Raj et al. (51) Breast Retrospective, 
pre-post study
186 women with breast cancer from a 
disadvantaged minority community who 
participated in a patient navigator program to 
improve quality measures
Women who received navigation services received high-quality 
cancer care, as defined by concordance with ASCO/NCCN 
quality measures. These navigated women also had a favorable 
breast cancer stage distribution with >50% having in situ or stage 
1 disease
Ramirez et al. (52) Breast Quasi-
experimental 
intervention
480 Latinas with breast cancer enrolled in 
either a patient navigation program for timely 
diagnostic resolution (n = 251) or usual care 
(n = 229) in the Six Cities Study
A significantly higher percentage of navigated women initiated 
treatment within 30 days (69.0 vs. 46.3%, p < 0.05) and 60 days 
(97.6 vs. 73.1%, p < 0.001) compared to women in the usual 
care group. Time from cancer diagnosis to first treatment was 
significantly lower in the navigated group (22.22 days) than usual 
care group (48.30 days)
Ulloa et al. (53) Breast Prospective, 
pre-post study
130 low-income women from California enrolled 
in a patient navigation intervention to improve 
communication about survivorship care
The intervention significantly improved short-term recall of 
patient-specific breast cancer knowledge (p = 0.05) and reduced 
communication barriers (15.0% at week 1 to 6% at 3 months, p < 0.05)
TABLe 1 | Continued
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the previous year, with the proportion increasing to 67% after 
1-year (p = 0.001) of receiving the education-based PN inter-
vention. Lastly, another study by Percac-Lima et al. (29) found 
that an education-based PN intervention to overcome barriers 
to breast cancer screening and information on how to obtain 
mammogram screening when needed among Somali, Arabic, 
or Serbo-Croatian refugee women improved mammography 
rates and significantly decreased disparities in screening rates 
between refugee and English- and Spanish-speaking women 
receiving care at the same health center.
One study in our review examined the impact of PN on 
screening rates for gynecological cancers. Wang et al. (31) found 
Chinese women in need of a Pap test reported significantly 
higher Pap test screening rates for those who received the PN 
intervention (education and PN services) compared to the 
control group (education only) (70 vs. 11.1%, respectively, 
p < 0.001).
PN for Diagnostic Resolution
Six studies (32, 35, 36, 38, 39, 45) were identified that focused on 
PN interventions to reduce time from abnormal breast cancer 
screening to diagnostic resolution. Of the six studies, one RCT 
by Lee et al. (39) examined the efficacy of PN among medically 
underserved populations in Tampa, FL, USA. Results showed 
a lagged effect of PN; PN did not increase the timeliness of 
diagnostic resolution during the initial 3  months of follow-up 
[adjusted hazard ratio (aHR)  =  0.85, 95% CI  =  0.64–1.13], 
but reduced the time to diagnostic resolution after 3  months 
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(aHR =  2.8395% CI =  1.30–6.13) and had a significant effect 
(p < 0.05) after 4.7 months. Several quasi-experimental studies 
(32, 36, 38, 45) on PN and diagnostic resolution for abnormal 
breast cancer screening reported that PN significantly shortened 
time to diagnostic resolution compared to women who did not 
receive PN. One cohort study (35) exploring patient perspectives 
of clinical care and PN in follow-up of abnormal mammography 
reported no differences in the timeliness of care, preparation 
for the visit to the breast center, ease of access, quality of care, 
provider communication, unmet needs, and patient satisfaction 
between navigated and non-navigated groups.
Three studies, a meta-analysis (42), descriptive study (40), 
and quasi-experimental study (43), were published during the 
time period reviewed that examined PN for diagnostic resolu-
tion of an abnormal cervical cancer screening result. A recent 
meta-analysis by Paskett et al. (42) examined the effectiveness 
of PN for diagnostic resolution of an abnormal cervical cancer 
screening among four PNRP centers. Within these centers, 
low-risk women in the navigated group showed improvement in 
timely diagnostic follow-up in all racial groups, but statistically 
significant effects were only observed in non-English speaking 
Hispanic women (OR = 5.88, 95% CI = 2.81–12.29). No effect 
was observed in high-risk women. A pre-post study (40) imple-
mented a PN program to reduce no-show rates at a colposcopy 
center. After implementation, no-show rates for abnormal Pap 
test follow-up declined from 49.7 to 29.5% (p <  0.0001). In 
another quasi-experimental study (43) focused on Latinas in 
need of abnormal Pap test follow-up, navigated women had 
significantly fewer missed colposcopy appointments over time 
(i.e., reduction from 19.8 to 15.7%; p = 0.02) compared with an 
insignificant increase in no-show rates from 18.6 to 20.6% in the 
comparison group.
Three studies (33, 34, 41) explored PN interventions with 
regard to diagnostic resolution after an abnormal breast or 
cervical cancer screening test. A study by Markossian et al. (41) 
reported PN for abnormal breast cancer screening was associ-
ated with shorter time to diagnostic resolution (aHR =  1.65, 
95% CI = 1.20–2.28, p = 0.002). However, there was a lag in the 
effectiveness of PN regarding diagnostic resolution for abnormal 
cervical cancer screening. In the first 30  days, the difference 
between those in the PN arm vs. those in the comparison group 
was not significant. But, from days 31 to 365, women in the PN 
group experienced a shorter time to diagnostic resolution com-
pared with those women who received usual care (aHR = 2.31, 
95% CI = 1.75–3.06, p < 0.001). A similar trend was noted by 
Battaglia et al. (33) among participants with an abnormal breast 
and cervical cancer screening test. Conversely, Charlot et  al. 
(34) found a language concordance PN intervention was associ-
ated with timelier resolution for the cervical cancer screening 
abnormalities group during the first 90 days (aHR = 1.46, 95% 
CI = 1.18–1.80), but not after 90 days. No significant difference 
was found between the navigated and non-navigated breast 
cancer screening abnormality groups throughout the course of 
the study.
The PNRP studies included other cancers (colorectal and 
prostate), but the majority of the cancers were breast and cervical. 
A meta-analysis by Freund et al. (37) assessed the timeliness of 
diagnostic resolution for an abnormal breast and cervical cancer 
screening result across the PNRP. The results of the meta-analysis 
found little benefit during the first 90 days of care as only one of 
the seven sites focusing on breast cancer screening and two of 
the four sites focusing on cervical cancer screening observed a 
positive effect of PN on time to diagnostic resolution (p < 0.05). 
Greater benefit from navigation was seen from 91 to 365  days 
for diagnostic resolution among three of the seven sites focused 
on breast cancer screening and two of the four sites focused on 
cervical cancer screening (p <  0.05). Meta-regression revealed 
that navigation had its greatest benefits within centers with the 
greatest delays in follow-up under usual care.
One study (44) reported on the difference in time to diagnos-
tic resolution between those in the PN intervention vs. control 
groups. A RCT from the Denver PNRP center evaluated the 
effectiveness of PN programs for increasing rates of diagnostic 
resolution for abnormal breast cancer screening. Raich et al. (44) 
found PN shortened time to resolution in the navigated group 
(p < 0.001) compared to the usual care group. Specifically, PN 
improved diagnostic resolution for patients presenting with 
mammographic BIRADS 0 and 3, but not BIRADS 4/5 or abnor-
mal breast examinations.
PN after Diagnosis
The results of the literature review for PN after cancer diagnosis 
resulted in eight studies (46–53), including one RCT (48), report-
ing effects on various outcomes among cancer patients including 
start of treatment, receipt of recommended care, completion of 
treatment, quality of life and depressive symptoms, communica-
tion with physicians, and quality measures. Hendren et al. (48) 
found no significant effect of PN on disease-specific quality of life 
scores between navigated and usual care breast cancer patients 
from baseline to 3 months. Other studies suggest that PN had no 
effect on time to completion of primary cancer treatment, sat-
isfaction with cancer-related care, or psychological distress, and 
they attributed the non-significant findings to the open eligibility 
criteria (all patients) instead of targeting those with shown need, 
as seen in other effective interventions (49, 51, 52).
A study by Ramirez et al. (52) sought to examine the effective-
ness of PN in reducing time from breast cancer diagnosis to ini-
tiation of treatment among Hispanic/Latino women. Compared 
to control patients, there was a significantly higher percentage 
of navigated women who initiated treatment within 30  days 
(69.0 vs. 46.3%, p < 0.05, intervention vs. control, respectively) 
and 60 days (97.6 vs. 73.1%, p < 0.001, intervention vs. control, 
respectively) from diagnosis. Also, time from breast cancer diag-
nosis to first treatment was significantly lower in the navigated 
group (22.22  days) than among women in the control group 
(48.30 days).
In a large, multisite study, Ko et  al. (49) sought to improve 
the receipt of recommended care for newly diagnosed breast 
cancer patients, and the findings varied based on the type of 
treatment received by the patients. Among women eligible for 
antiestrogen therapy, navigated participants were more likely 
to receive antiestrogen therapy compared with usual care par-
ticipants (OR =  1.73, p =  0.004). Among women eligible for 
radiation therapy after lumpectomy, navigated participants were 
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no more likely to receive radiation than usual care participants 
(OR = 1.42, p = 0.22).
Barriers to Care and PN
Several studies have conducted secondary analyses to understand 
the association between barriers to care and clinical outcomes, 
particularly within the PNRP. A 2015 study by Ramachandran et al. 
(54) explored the association among number of barriers to care, 
type of barriers, and timeliness of diagnostic resolution among 
women with abnormal cancer screening results. They found that 
74% of breast cancer screening participants and 55% of cervical 
cancer screening participants reported at least one barrier to diag-
nostic resolution. Navigated women with barriers resolved cancer 
screening abnormalities at a slower rate compared with navigated 
women with no barriers. Another study by Ramachandran et al. 
(55) using Boston PNRP data, found the odds of timely diagnos-
tic resolution reduced as the number of barriers increased (one 
barrier, aHR = 0.81, 95% CI = 0.56–1.17, p = 0.26; two barriers, 
aHR = 0.55, 95% CI = 0.37–0.81, p = 0.0025; three or more bar-
riers, aHR = 0.31, 95% CI = 0.21–0.46, p < 0.0001). Lastly, Katz 
et  al. (56) examined the effect of having barriers to diagnostic 
resolution and time to resolution among participants in the PN 
intervention arm with a breast or cervical cancer abnormal-
ity in the PNRP. They found that 63.7% of breast abnormality 
and 46.6% of cervical abnormality participants had at least one 
barrier resulting in longer time to diagnostic resolution among 
breast (aHR = 0.74, 95% CI = 0.67–0.83, p < 0.01) and cervical 
(aHR = 0.79, 95% CI = 0.70–0.90, p < 0.01) participants vs. those 
with no reported barriers.
Specific types of barriers patients report were described 
by several studies (57–59). Korber et  al. (57) found the most 
common barriers to cancer treatment were patient-provider 
communication and knowledge of patient resources. Other 
studies found location of health-care facility (59), transportation 
problems (58), not speaking English (55), no insurance (56), 
financial concerns (58, 60), lack of social/practical support (58, 
59), and lack of information about the abnormality (57) as the 
most prevalent barriers to cancer care among patients enrolled 
in PN interventions.
Some studies have attempted to determine which variables 
are associated with having a barrier to cancer care to identify 
women most in need of PN. Several studies (55, 60–62) found 
that women with barriers to cancer care were more likely to be 
racial and ethnic minorities (55, 60), unmarried (62), part-time 
employed/unemployed (60, 62), non-English language speakers 
(55, 61), and have public/no health insurance (55, 60) compared 
to women without any barriers to care.
DiSCUSSiON
As evidenced in this literature review, PN has been shown to 
help women receive cancer screenings, receive more timely 
diagnostic resolution after a breast and cervical cancer screening 
abnormality, initiate treatment sooner, receive proper treatment, 
and improve quality of life among cancer patients. Also, it was 
shown that PN eliminates barriers to care. PNRP demonstrated: 
(1) who has barriers; (2) that barriers delay the receipt of care; 
and (3) types of numbers of barriers that impact time to treatment 
(54–56).
Several trends emerged from this review. PN programs 
have been implemented among diverse populations specifically 
focused on reducing health disparities in racial and ethnic 
minorities and/or underserved populations. It is important to 
note that each study population and setting was unique, thus 
generalizability of these findings may be limited. Another trend 
noted was the limited effectiveness for certain groups receiving 
PN, alluding to the possibility that PN is not equally effective for 
all groups. Results found significant differences in PN effective-
ness with regard to age (32), ethnicity (42), location of care (37), 
type of screening test (38), and type of treatment (49). Although 
relevant for all populations, use of a “one-size-fits all” approach to 
PN may not be the best approach. The original intent of PN is to 
improve the experience of care among patients with the greatest 
needs by tailoring actions to an individual’s barriers to care (63). 
If implementation across the patient population is too demanding 
on resources, especially due to the fact that the American College 
of Surgeons Commission on Cancer (CoC)’s accreditation man-
dates are currently unfunded, targeting PN implementation may 
be a possible solution. By identifying those most likely to need 
PN, scarce resources can be diverted to women in most need and 
most likely to delay or not receive prompt, appropriate care (64).
Finally, although there is evidence of the potential of PN to 
improve outcomes related to cancer screening and diagnostic 
resolution, many studies have utilized less robust designs (i.e., 
quasi-experimental and descriptive studies), as mentioned by 
previous reviews (14–16). A notable difference between this 
review and the prior reviews is an increase in the number of stud-
ies evaluating PN on cancer screening and treatment outcomes. 
Another difference between this and previous reviews was inclu-
sion of studies that evaluated the association of PN with reported 
outcomes during cancer treatment and post-treatment. Yet, there 
was great heterogeneity among the studied outcomes (e.g., qual-
ity of life, proper treatment), and therefore, cumulative evidence, 
as seen in PN interventions on cancer screening and diagnostic 
resolution, is lacking.
Research Opportunities in PN and 
women’s Health
Due to the increased prevalence of PN in health-care systems, 
there are growing research opportunities in PN and women’s 
health. One area that is ripe for researchers is PN in cancer sur-
vivorship, particularly among post-treatment cancer survivors. 
Increases in the number of individuals diagnosed with cancer 
each year, as well as improving survival rates, have led to an 
ever-increasing number of cancer survivors (20). As evidenced 
by this review, implementation of PN interventions among post-
treatment cancer survivors is lacking. Future research should not 
only explore adherence to post-treatment surveillance behaviors 
but also treatment outcomes that can affect the physical and 
psychological well-being of women.
The PN literature on women’s cancers is growing; however, 
it is limited in that researchers have primarily focused on breast 
cancer (as seen in the literature on PN after diagnosis). Although 
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cervical cancer incidence and mortality rates have steadily 
decreased, it is estimated that in 2015, 12,900 new cases of inva-
sive cervical cancer occurred and 4,100 died from this disease 
(19). There is a wide racial and socioeconomic disparity in the 
incidence and mortality rates from cervical cancer. Underlying 
these disparities are often education, language, geographic, and 
trust factors (65). As evidenced by this review, the few studies 
that have explored PN in gynecological cancers showed promis-
ing results. Thus, researchers should make gynecological cancers 
a focus for their PN interventions to maximize the positive 
impact on this survivor population. Important yet understudied 
subpopulations, such as women with increased genetic risk, 
should be considered. PN can provide education, support, and 
guidance within the clinical setting for these women to receive 
appropriate screenings, genetic testing and counseling, prompt 
diagnosis, and proper treatment.
Women may also benefit from PN during cancer care that 
is tailored to specific family-related barriers, such as child care 
and transportation. Women often assume the role of caregivers 
and income-earners and may need more assistance in caregiv-
ing for others while receiving cancer care for themselves. PN 
can link them to resources that offer emotional (i.e., support 
groups) and tangible support (i.e., house cleaning, child care) 
and has the potential to improve quality of life and psychosocial 
outcomes for both women with cancer and women who are 
caregivers.
Navigators should consider the age of the female patient and 
their stage in life during PN interventions. For example, younger 
women often face very different challenges and complications 
than older women, including concerns about becoming a 
mother; caring for children when faced with a life-threatening 
illness; premature menopause leading to loss of fertility; sudden 
onset of vasomotor symptoms; long-term consequences of early 
ovarian decline; body image and sexuality; and career and work 
concerns related to productivity and job security (66). For older 
adults, age-related concerns may include spousal caregiving; lack 
of social support; quality vs. quantity of life; comorbidities; risk 
of polypharmacy; mobility challenges; housing and transporta-
tion needs; and declining cognitive function and information 
processing (67, 68). Navigators from the PNRP used a standard-
ized, structured list and an open-ended approach that captured 
barriers to care identified by participants. Future studies should 
utilize this approach to collect information on barriers to care 
and explore age-related differences in reported barriers to address 
individual needs accordingly.
The similarity of patient navigators to the participants is 
important for the success of PN interventions. For example, 
patient navigator race and language concordance improved the 
timeliness of care in a minority population (34). Likeness to the 
patient population is already a typical characteristic of CHWs, 
who work within a target community to improve community 
awareness and adherence to cancer screenings, and thus, this 
successful strategy should be extended to navigators. Since 
the CHWs’ role is to connect underserved populations from 
the community with screening services, PN programs should 
work with CHWs to assist women across the entire cancer 
care spectrum from cancer prevention to post-treatment. 
Future research should explore the effect of a combined CHW 
and PN intervention to increase community engagement, 
improve access to preventive health services, facilitate timely 
diagnosis and treatment, and ultimately improve the health 
of women in underserved areas.
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